386 related articles for article (PubMed ID: 21507143)
1. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.
Long W; Deng X; Zhang Y; Lu G; Xie J; Tang J
Respirology; 2011 Jul; 16(5):819-24. PubMed ID: 21507143
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.
Christ-Crain M; Stolz D; Bingisser R; Müller C; Miedinger D; Huber PR; Zimmerli W; Harbarth S; Tamm M; Müller B
Am J Respir Crit Care Med; 2006 Jul; 174(1):84-93. PubMed ID: 16603606
[TBL] [Abstract][Full Text] [Related]
3. [The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient].
Long W; Deng XQ; Tang JG; Xie J; Zhang YC; Zhang Y; Gao YY; Lu G
Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):216-9. PubMed ID: 19576090
[TBL] [Abstract][Full Text] [Related]
4. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia.
Esposito S; Tagliabue C; Picciolli I; Semino M; Sabatini C; Consolo S; Bosis S; Pinzani R; Principi N
Respir Med; 2011 Dec; 105(12):1939-45. PubMed ID: 21959024
[TBL] [Abstract][Full Text] [Related]
5. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
6. How to reduce antibiotic consumption for community-acquired pneumonia?
Montassier E; Goffinet N; Potel G; Batard E
Med Mal Infect; 2013 Feb; 43(2):52-9. PubMed ID: 23433607
[TBL] [Abstract][Full Text] [Related]
7. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.
Schuetz P; Christ-Crain M; Thomann R; Falconnier C; Wolbers M; Widmer I; Neidert S; Fricker T; Blum C; Schild U; Regez K; Schoenenberger R; Henzen C; Bregenzer T; Hoess C; Krause M; Bucher HC; Zimmerli W; Mueller B;
JAMA; 2009 Sep; 302(10):1059-66. PubMed ID: 19738090
[TBL] [Abstract][Full Text] [Related]
8. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.
Perren A; Cerutti B; Lepori M; Senn V; Capelli B; Duchini F; Domenighetti G
Infection; 2008 Mar; 36(2):163-6. PubMed ID: 18330505
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of serum procalcitonin in identifying the etiology of non-responding community-acquired pneumonia after initial antibiotic therapy].
Wang Z; Zhang X; Wu J; Zhang W; Kuang H; Li X; Xuan W; Wang K; Ma L
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Nov; 37(11):824-30. PubMed ID: 25604112
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
12. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.
Christ-Crain M; Jaccard-Stolz D; Bingisser R; Gencay MM; Huber PR; Tamm M; Müller B
Lancet; 2004 Feb; 363(9409):600-7. PubMed ID: 14987884
[TBL] [Abstract][Full Text] [Related]
13. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
14. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
[TBL] [Abstract][Full Text] [Related]
15. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
16. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.
Nobre V; Harbarth S; Graf JD; Rohner P; Pugin J
Am J Respir Crit Care Med; 2008 Mar; 177(5):498-505. PubMed ID: 18096708
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial.
Masiá M; Padilla S; Ortiz de la Tabla V; González M; Bas C; Gutiérrez F
PLoS One; 2017; 12(4):e0175634. PubMed ID: 28426811
[TBL] [Abstract][Full Text] [Related]
18. The value of procalcitonin level in community-acquired pneumonia in the ED.
Park JH; Wee JH; Choi SP; Oh SH
Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
[TBL] [Abstract][Full Text] [Related]
19. [Value of serum procalcitonin for the guidance of antibiotic therapy in children with lower respiratory tract infection].
Dai BQ; Yuan XT; Liu JM
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Dec; 17(12):1292-6. PubMed ID: 26695667
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial.
Maravić-Stojković V; Lausević-Vuk L; Jović M; Ranković A; Borzanović M; Marinković J
Srp Arh Celok Lek; 2011; 139(11-12):736-42. PubMed ID: 22338468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
